TransCode Therapeutics to Present Phase 1a Clinical Trial Data for TTX-MC138 at ESMO Congress 2026
PR Newswire•19/10/2026•08:04 ET
1
Key Highlights
- ➤Phase 1a TTX-MC138 data accepted for ESMO Congress 2026 presentation
- ➤Poster presentation scheduled October 23 in Madrid, Spain
- ➤TTX-MC138 targets miR-10b associated with metastatic disease progression
- ➤TTX-MC138 also undergoing Phase 2a evaluation under PRE-I-SPY
Expert Statements
Zdravka Medarova, Chief Scientific Officer of TransCode Therapeutics
“We are honored to have the opportunity to present our most recent TTX-MC138 clinical results at ESMO, one of the world's leading oncology meetings.”
Zdravka Medarova, Chief Scientific Officer of TransCode Therapeutics
“This poster provides an opportunity to share our clinical experience with TTX-MC138 with the global oncology community and highlight our continued development of this novel therapeutic approach.”
TransCode Therapeutics to Present Phase 1a Clinical Trial Data for TTX-MC138 at ESMO Congress 2026 PR Newswire
Poster presentation to highlight the Phase 1a clinical evaluation of TTX-MC138 in patients with advanced solid tumors
Get started
Create a free account to read the full story.